- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04550104
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)
A Platform Study of DNA Damage Response Inhibitors in Combination With Conventional Radiotherapy in Non Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Radiotherapy is an effective treatment for patients with non-small cell lung cancer (NSCLC) that has not spread beyond the chest area. Radiotherapy is used as a curative treatment but unfortunately for most patients the cancer can return. Radiotherapy kills cells by damaging their DNA. Cells have the ability to repair that damage, especially the cells of normal tissue. If DNA repair can be prevented radiotherapy should be more effective causing the cancer cells to die.
The study will use new drugs that affect how cells repair DNA damage, called DNA damage response inhibitors (DDRi). These will be given together with radiotherapy to hopefully improve the effectiveness of radiotherapy, followed by up to 12 months of durvalumab immunotherapy in selected study arms to develop the trial in line with the standard of care for NSCLC. The study will try to find out the most effective and safe dose of this combination treatment. This will be a clinical trial where patients due to have radiotherapy, with the hope of successful treatment that could lead to cure from their cancer or extension of life, will be offered entry onto the study. All patients will receive their radiotherapy, with 3 out of every 4 people also receiving a single DDRi drug alongside this. Both patients and study doctors will know prior to the start of the actual treatment whether a DDRi will be given, and if so which one; no placebos will be used. The patients will be followed closely to check for side effects and to assess how their cancer is responding to treatment. Blood samples will be taken to monitor treatment progress and to try to predict which patients are most likely to benefit from this type of combined treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jamie B Oughton, MPhil
- Phone Number: 0113 343 1494
- Email: CTRU_CONCORDE@Leeds.ac.uk
Study Locations
-
-
-
Belfast, United Kingdom
- Recruiting
- Belfast City Hospital
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Jonathan McAleese
-
Cambridge, United Kingdom
- Recruiting
- Addenbrooke's Hospital
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Huiqi Yang
-
Cardiff, United Kingdom
- Recruiting
- Velindre Cancer Centre
-
Principal Investigator:
- Paul Shaw
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Chelsea, United Kingdom
- Recruiting
- The Royal Marsden Hospital Chelsea
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Merina Ahmed
-
Edinburgh, United Kingdom
- Recruiting
- Western General Hospital
-
Principal Investigator:
- Stephen Harrow
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Leeds, United Kingdom
- Recruiting
- St James's University Hospital
-
Principal Investigator:
- Kevin Franks
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
London, United Kingdom
- Recruiting
- University College Hospital London
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Crispin Hiley
-
Manchester, United Kingdom
- Recruiting
- The Christie NHS Foundation Trust
-
Principal Investigator:
- Corinne Faivre-Finn
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Clara Chan
-
Newcastle Upon Tyne, United Kingdom
- Recruiting
- Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust
-
Contact:
- Alastair Greystoke
- Email: ctru_leeds@leeds.ac.uk
-
Principal Investigator:
- Adam Hassani
-
Sheffield, United Kingdom
- Recruiting
- Weston Park Hospital
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Matthew Hatton
-
Sutton, United Kingdom
- Recruiting
- The Royal Marsden Sutton
-
Contact:
- Email: CTRU_CONCORDE@leeds.ac.uk
-
Principal Investigator:
- Merina Ahmed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Core Inclusion Criteria (Radiation Phase)
- Histologically or cytologically confirmed NSCLC (patients where the local MDT agree the diagnosis is NSCLC after review of the available pathology and imaging at MDT can be enrolled after discussion with the CI).
- Not suitable for concurrent chemoradiotherapy/surgery due to tumour or patient factors
- Stage IIB and III (TNM 8th Edition).
- Planned to receive RT at curative intent doses (i.e., 60Gy) as part of treatment plan (either with or without induction chemotherapy).
- Patient considered suitable for radical RT by the local lung cancer multidisciplinary team and a clinical oncologist.
- If chemotherapy has been given previously, the maximum interval between the last day of chemotherapy and the start of RT <10 weeks.
- Age ≥18
- Life expectancy estimated to be greater than 6 months.
- Karnofsky Performance status ≥70.
- MRC dyspnoea score <3.
- Forced expiratory volume in one second (FEV1) ≥35% predicted and diffusing capacity of the lungs for carbon monoxide (DLCO or TLCO) ≥35% predicted.
- Patient must be fully informed about the study and have signed the informed consent form.
- Patient must be willing and able to comply with the protocol, have mental capacity and (if relevant) use effective contraception throughout treatment and for 4 months for women of childbearing potential, and 6 months for men after treatment completion. Treatment is defined as including the last dose of durvalumab or DDRi in the consolidation phase.
- Adequate organ function as defined in master protocol.
- Patient has a body weight of >30kg.
Core Exclusion Criteria (Radiation Phase)
- Mixed non-small cell and small cell tumours.
- Confirmed progressive disease during induction chemotherapy.
- Participation in a study of an investigational agent or using an investigational device within 4 weeks prior to the anticipated start of treatment.
- Current or previous malignant disease which may impact on a patient's estimated life expectancy (other than NSCLC).
- History of interstitial pneumonitis.
- Prior thoracic radiotherapy.
- Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then exclude if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.
- Mean resting corrected QT interval (QTcF) >470 msec obtained from 3 electrocardiograms.
- Received a prior autologous or allogeneic organ or tissue transplantation.
- Patients unable to swallow orally administered medications or chronic gastrointestinal (GI) disease likely to interfere with absorption of IMP in the opinion of the treating investigator (e.g. malabsorption syndrome, resection of the small bowel, poorly controlled inflammatory bowel disease etc.).
- Grade 2 or higher peripheral sensory neuropathy.
- Known positive test for human immunodeficiency virus, active hepatitis B or C infection.
- Positive pregnancy test (at eligibility assessment for women of childbearing potential) or breast-feeding women.
- Patients with persistent toxicities (>CTCAE grade 2) caused by previous cancer therapy, excluding alopecia.
- Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
- Major surgery within 2 weeks of confirmation of eligibility.
- Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease or active uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, uncontrolled hypertension, uncontrolled atrial fibrillation, active bleeding, recent (within 3 months) myocardial infarction, major seizure, active COVID-19, any psychiatric disorder that prohibits obtaining informed consent.
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.
- Exclusions as described in the relevant study arm protocol. Patients ineligible for a particular study arm may be considered for entry into an alternative study arm if an appropriate slot is available and they meet all the inclusion and exclusion criteria for that arm. This will need to be discussed with CTRU and the patient will be required to reconsent using the appropriate study arm PIS/ICF.
Core Inclusion Criteria (Consolidation Phase)
- A minimum of 4 and a maximum of 8 weeks* have elapsed following completion of RT
- Any toxicities from RT have resolved to grade 1. If patient has pneumonitis following RT treatment, this must be asymptomatic (grade 1). If pneumonitis is ≥2 or requiring steroids, then participant is not eligible
- Karnofsky Performance status ≥70
- The laboratory requirements set out in Table 1 of the master protocol are met
- Patient has no known hypersensitivity to the excipients of durvalumab
- Patient has body weight of >30kg *Investigators should ideally aim to start consolidation treatment within 6 weeks, following the receipt of the CT scan results to rule out progression.
Core Exclusion Criteria (Consolidation Phase)
- Progressive disease during RT or at the end of RT treatment response assessment.
- Participant declines treatment in the consolidation phase.
- Patients who have received prior anti-PD-1 or anti PD-L1 treatment.
- Major surgery within 4 weeks of confirmation of eligibility for consolidation phase.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
- Patients considered a poor medical risk by the investigator due to a serious, uncontrolled medical disorder, non-malignant system disease, active GI infection or active uncontrolled infection.
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease e.g., colitis or Crohn's disease), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Radiotherapy only
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
|
Experimental: Olaparib + radiotherapy
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
Oral tablet
Other Names:
|
Experimental: AZD1390 + radiotherapy
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
Oral tablet
|
Experimental: Ceralasertib (AZD6738) + radiotherapy + Consolidation durvalumab
This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
Oral Tablet
Other Names:
1500mg iv infusion
|
Experimental: AZD5305 + radiotherapy + Consolidation durvalumab
This study arm will include up to 12 months of consolidation durvalumab for eligible participants following the completion of radiotherapy +/- DDRi.
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
1500mg iv infusion
Oral Tablet
|
Active Comparator: RT + consolidation durvalumab
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
1500mg iv infusion
|
Experimental: Arm D - did not proceed
|
Administered as 30 fractions of 2Gy.
Total 60 60Gy.
Administered once daily monday to friday.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting Toxicities
Time Frame: 13.5 months after start of radiotherapy
|
Dose-limiting toxicities (DLTs), within 13.5 months of starting radiotherapy, in order to establish the Recommended Phase II Dose (RP2D) of each DDRi-RT combination.
|
13.5 months after start of radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and toxicity
Time Frame: 2 years after end of RT
|
Safety will be reported based on the occurrence of SAEs, SARs and SUSARs.
Toxicity will be reported based on adverse events, as graded by CTCAE V5.0, and determined by routine clinical assessments at each centre.
|
2 years after end of RT
|
Treatment compliance
Time Frame: End of trial treatment (DDRi and RT)
|
Treatment compliance will be measured by overall radiotherapy treatment time and delays, omissions and reductions to treatment doses (both DDRi and RT).
|
End of trial treatment (DDRi and RT)
|
Best overall response
Time Frame: 2 years after end of RT
|
Best overall response will be measured as the best response (complete response, partial response or stable disease) recorded until disease progression, reported up to 2 years post-RT.
This will be assessed using RECIST 1.1
|
2 years after end of RT
|
Disease control
Time Frame: 2 years after end of RT
|
This will be assessed using the Green Criteria.
Disease Control includes either the complete disappearance of all evidence of malignant disease or residual radiographic abnormalities assessed by chest CT scan at 3 and 6 months after completion of RT, which then remains stable for an additional 6 months or more and which then qualifies as controlled local disease.
|
2 years after end of RT
|
Progression-free survival
Time Frame: 2 years post-RT
|
Participants who have not progressed at the time of analysis will be censored at the last date they were known to be alive and progression free
|
2 years post-RT
|
Overall survival
Time Frame: 2 years post-RT
|
Participants who have not died at the time of analysis will be censored at the last date they were known to be alive
|
2 years post-RT
|
Changes in Health Related Quality of Life
Time Frame: 2 years after end of RT
|
Health Related Quality of Life will be determined using EORTC QLQ-C30, IL-73 and IL-74
|
2 years after end of RT
|
Objective response rate
Time Frame: 2 years after end of RT
|
Objective response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy.
The proportion of patients with evaluable scans that achieve at least a partial response, as defined by RECIST v1.1(31), will be presented with 95% confidence intervals.
|
2 years after end of RT
|
Changes in tumour size during and following treatment with DDRi-RT compared to RT alone.
Time Frame: 2 years after end of RT
|
2 years after end of RT
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of mutations in components of DDR pathway in archival tumour and cfDNA prior to therapy
Time Frame: 2 years after end of RT
|
Exploratory endpoint
|
2 years after end of RT
|
Assessment of T cells within the archival tumour specimens
Time Frame: 2 years after end of RT
|
Exploratory endpoint
|
2 years after end of RT
|
Changes in cfDNA during and following treatment with DDRi-RT compared to RT alone.
Time Frame: 2 years after end of RT
|
Exploratory endpoint
|
2 years after end of RT
|
Changes in circulating biomarkers of cardiac and respiratory toxicity during and following treatment with DDRi-RT compared to RT alone.
Time Frame: 3 months post end of RT
|
Exploratory endpoint
|
3 months post end of RT
|
Changes in circulating peripheral T cell sub-sets during and following treatment with DDRi-RT compared to RT alone.
Time Frame: 2 years after end of RT
|
Exploratory endpoint
|
2 years after end of RT
|
Changes in lung parenchyma during and following treatment with DDRi-RT compared to RT alone.
Time Frame: 2 years after end of RT
|
Exploratory endpoint
|
2 years after end of RT
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Alastair Greystoke, MB ChB, MSc, PhD, Newcastle University
- Principal Investigator: Corinne Faivre-Finn, MD, PhD, University of Manchester
Publications and helpful links
General Publications
- Faivre-Finn C, Brown S, Ryan A, Greystoke A; CONCORDE Investigators. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform. Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24. No abstract available.
- Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Poly(ADP-ribose) Polymerase Inhibitors
- Olaparib
- Durvalumab
Other Study ID Numbers
- MO20/118073
- 2020-000206-28 (EudraCT Number)
- 282001 (Other Identifier: IRAS)
- A28890 (Other Grant/Funding Number: Cancer Research UK)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data datasets generated and/or analysed during the current study will be available upon request from the Clinical Trials Research Unit, University of Leeds. Data will be made available at the end of the trial. Data will remain available from then on for as long as CTRU retains the data.
CTRU makes data available by a 'controlled access' approach. Data will only be released for legitimate secondary research purposes, where the Chief Investigator, Sponsor and CTRU agree that the proposed use has scientific value and will be carried out to a high standard (in terms of scientific rigour and information governance and security), and that there are resources available to satisfy the request. Data will only be released in line with participants' consent, all applicable laws relating to data protection and confidentiality, and any contractual obligations to which the CTRU is subject.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Contact CTRU-DataAccess@leeds.ac.uk in the first instance.
No individual participant data will be released before an appropriate agreement is in place setting out the conditions of release. The agreement will govern data retention, usually stipulating that data recipients must delete their copy of the released data at the end of the planned project.
The CTRU encourages a collaborative approach to data sharing, and believe it is best practice for researchers who generated datasets to be involved in subsequent uses of those datasets. Recipients of trial data for secondary research will also receive data dictionaries, copies of key trial documents and any other information required to understand and reuse the released datasets.
The conditions of release for aggregate data may differ from those applying to individual participant data. Requests for aggregate data should also be sent to the above email address to discuss and agree suitable requirements for release.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
UNICANCERNational Cancer Institute, FranceRecruitingBreast Cancer | DCIS | Low Risk DCIS | Breast Conserving Surgery | Radiotherapy OmissionFrance
-
University Medical Center GroningenCatharina Ziekenhuis Eindhoven; Academisch Medisch Centrum - Universiteit van... and other collaboratorsActive, not recruiting
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands
-
Radboud University Medical CenterKoningin Wilhelmina Fonds; Maastro Clinic, The NetherlandsTerminatedSpinal MetastasesNetherlands
-
National University Hospital, SingaporeTan Tock Seng HospitalUnknownGastric CancerSingapore
-
IRCCS San RaffaeleRecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, ClinicalItaly